Studies on the performance of Saudi Arabia in the pharmaceutical science research using quantitative and qualitative measures. They analyze the productivity and global publication share and rank of the top 15 countries. The author studies Saudi Arabia's publications output, growth and citation quality, international collaborative publication share and most important the collaborating partners, contribution and citation impact of its top 15 organizations and authors, productivity patterns of its top publishing journals and characteristics of its highly cited papers.
Introduction
Despite of incredible advances in the diagnosis and treatment of various diseases, the incidence, prevalence, morbidity and mortality resulting from these diseases continue to escalate.
Regardless, the wealth of information in internet, latest research trends, and many other health databases and increasing number of drugs available in the market, the progress to reduce medical need and disease burden is low in both developed and under developed countries. For ages, pharmaceutical products have been one of the main therapeutics to the majority of the less privileged population. The potential of the drugs has attracted the attention of the developed world, to tap their benefits to identify better and safe drugs to combat human diseases, while in the poor nations these products continue to provide health benefits to the diversified categories of patients (Fura, 2006; Gyo¨rgy and Gergely, 2006) . The combined efforts of all public and private R&Ds worldwide bring around only few drugs directed against completely novel mechanisms successfully to market each year. Most drugs have had some therapeutic benefit, and some had phenomenal impact on mortality and morbidity, such as the anti-tumor agents. However, in many diseases, for e.g. HIV, Diabetes, and Cancer the cure has not been identified yet. The impact of genomics and proteomics is additionally creating an explosion in the number of drug targets. Today's drug therapies are based solely on approximately 500 biological targets, while, in 10 years' time, the number of targets could well reach 10,000. The increasing demand for new small molecules led to the invention of new technologies in the field of Pharmaceutical Sciences. Everincreasing understanding of trends in pharmaceutical research, the community continues to struggle with finding solutions to identify lead molecules (William and Lloyd, 1998; Stephen et al., 2002) . The present study is focused on an oil rich country of Middle East, the Kingdom of Saudi Arabia. With emerging globalization of science and education, the challenge of education and research needs in Saudi Arabia has opened new frontiers. As it is moving forward in most of the areas of research and setting up many research centers all over the country, majority of Saudi universities' prime interest is at advancing research in individual fields and enhancing the research atmosphere (AlAli, 2000; Simon and Yousif, 2012) . The greatest breakthrough during recent years is expanding the role of pharmacists in the developing countries (Yousif, 2011) . Saudi Arabia sets as an example of identifying the primary role in clinical pharmacy, drug discovery and research. Hence, pharmaceutical research is at the forefront and one of the strategic priorities in Saudi Arabia. Our main aim is to study and analyze the research output of Saudi Arabia and to identify highly productive institutes and authors. Few scientometric studies have been published in this area. Reddy and Mahesh Kumar (2006) provide a scientometric analysis of world papers published by 57 countries in 10 major sub-specialities appearing in three leading international journals during the ten year period. Dotson et al. (2011) analyzed changes in the authorship and characteristics of articles in pharmacy journals during the 20 year period. In the field of bibliometrics of country output in pharmacology only a few studies have been carried out on India (Kaur and Gupta, 2009; Ahila et al., 2011; Gupta et al., 2011) , China (Li et al., 2010) and Spain (Bordon and Barrigon, 2005) which deal with different facets of pharmacological research, its growth, global publication share and rank, international collaboration, institutional and authors productivity profile, etc.
Objectives
The main objective of present analysis in this paper is to analyze the Saudi Arabian contribution in the pharmaceutical research during the last 10 years from 2001-10 with a view: (i) to study the productivity profile of the world's top 15 most productive countries; (ii) to study the Saudi Arabian research output, citation impact, and international collaboration share and identify the leading collaborating partner countries; (iii) to study the contribution and citation impact of its most productive institutions & authors; (iv) to study the media of communication in most productive journals, and (v) to study the characteristics of highly cited papers.
Methodology and source used
This study was undertaken based on the publication data from Saudi Arabia and also identifies the top 15 most productive countries in the field of pharmaceutical research. Data for the present study were retrieved from the Scopus international multidisciplinary bibliographical database [http://www.scopus.com/search/] for the last ten years (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) . The search strategy string used to retrieve the main data on research output, institutions, authors and major journals of Saudi Arabia is as follows: For citations data, three year, two year and one year citations window has been used for computing average citations per paper from Saudi Arabia during 2001-2008, 2009 and 2010 . For searching and calculating the total international collaborative papers, a separate search strategy, which combines Saudi Arabia's collaboration with 140 major countries, was also prepared.
Analysis

Global publication output in pharmaceutical sciences
The publication output of the top 15 most productive countries ranges from 1.35% to 24.49% during 2001-10. The largest contribution is made by USA with 24.49% share, followed far behind by China (7.47% share), Japan (7.42% share), U.K (6.49% share), Germany (5.64% share), India (5.37% share), Italy, France, Canada, Spain and South Korea (with publication share varying from 2.34% to 3.91%), Brazil, Netherlands, Australia and Switzerland (with publication share varying from 1.35% to 1.90%). The publication share has increased in China by 5.8%, followed by India (3.57%), Brazil (0.89%), South Korea (0.75%), Italy (0.38%), Australia (0.21%) and Switzerland (0.07%), as against decrease by 1.28% in Japan, followed by Germany (0.39%), U.K (0.36%), Spain (0.35%), France and Netherlands (0.27% each), USA (0.18%) and Canada (0.11%) from 2001-05 to 2006-10. In terms of publication rank, countries which have improved their global rank are China (from 5th to 2nd), India (from 8th to 3rd), Canada (from 10th to 9th), South Korea (from 12th to 11th) and Brazil (from 14th to 12th), in contrast to countries losing their rank such as Japan (from 2nd to 4th), UK (from 3rd to 5th), Germany (from 4th to 6th), France (from 6th to 8th), Spain (from 9th to 10th) and Netherlands (from 11th to 14th) from 2001-05 to 2006-10. For other countries, global publications rank has remained the same during the above mentioned period (Table 1) .
Saudi Arabia's publication output, citation impact and international collaboration
The research output of Saudi Arabia in pharmaceutical science consists of 1386 papers during 2001-10, which has increased from 111 papers in 2001 to 301 papers in 2010, registering an annual average growth rate of 14.21%. The cumulative research output of Saudi Arabia in pharmaceutical science has increased from 567 papers during 2001-05 to 819 papers during 2006-10, witnessing a growth rate of 44.44%. The global share of Saudi Arabia was only 0.50% during 2001-10. The average citation impact per paper registered for total papers in pharmaceutical science of Saudi Arabia was 3.36, which marginally decreased from 3.38 during 2001-05 to 3.35 during 2006-10 ( Table 2) .
The international collaborative output of Saudi Arabia in pharmaceutical science consists of 562 papers, constituting 40.55% share of its total publications output during 2001-10. The share of international collaborative output of Saudi Arabia has increased from 32.45% during 2001-05 to 46.15% during 2006-10 (Table 2) . Of the total international collaborative papers published by Saudi Arabia in pharmaceutical science with different countries, 15 countries have published 8 or more papers. The largest number of international collaborative papers (247 papers, 43.95% share) of Saudi Arabia is published with Egypt, followed by USA (88 papers, 15.66% share), India (70 papers, 12.46% share), U.K. (Table 3) .
Focus of pharmacological research
3.3.1.Organs
If we study organ-wise the focus of research, we can get ideas regarding the nature of pharmaceutical research being probed in Saudi Arabia. The maximum focus of pharmaceutical research in Saudi Arabia during 2001-10 has been on liver (with 169 papers), followed by kidney (102 papers), heart (84), muscle (56), stomach (49), skin (48), brain (43), breast (42), eye (16), artery (14), pancreas (12), ear (8), throat (5), genital (4), feet (3) and neck (2).
Disease
The maximum output of pharmaceutical research has been reported on cancer (with 149 papers), followed by heart diseases (104 papers), diabetes (61 papers), respiratory infection (26 papers), blood disorders (22), tuberculosis (15), depression (14 papers), HIV/AIDS (10), diarrhea (10), epilepsy (10 papers), pneumonia (9), malaria (9), hepatitis (9 papers), cirrhosis (6), leishmaniasis (6), etc.
Pharmacological activity
The largest pharmaceutical activity reported in the literature was on enzyme activity (with 125 papers), followed by anti-oxidant activity (87 papers), anti-neoplastic activity (70 papers), anti-inflammatory activity (54 papers), anti-microbial activity (40 papers), anti-bacterial activity (27 papers), anti-fungal activity (22 papers), analgesic activity (20 papers), anti-viral activity (17 papers), etc.
Most productive organizations -contribution and impact
The 
Most productive authors -contributions and impact
As seen in Table 5 ].
Research communication in high productive journals
The 15 most productive domestic and foreign journals publishing Saudi Arabian research papers together contributed 524 papers in pharmaceutical science, which accounted for 37.81% of the total output of Saudi Arabia during 2001-10. The cumulative share of these 15 journals in total publications output of Saudi Arabia in pharmaceutical science has decreased from 45.50% during 2001-05 to 32.48% during 2006-10 (Table 6 ).
Highly cited papers
There are 19 Saudi Arabian papers, which have received 50 or more citations since their publication till 22 February 2012 (Table 7) . These are referred here as high cited papers. Of the 19 high cited papers, 10 have appeared as articles and 9 as reviews. Of the 19 high cited papers, 5 were international (4 bilateral and 1 multilateral) collaborative. Of the 19 high cited papers, 1 paper falls in the citation range of 201-227, 2 papers fall in the citation range of 100-199 and 16 papers fall in the citation range of 50-99. These 19 high cited papers have received 1566 citations, with an average of 82.42 citations per paper and the citation range of these papers varies from 50 to 227. These 19 high cited papers involve 7 Saudi Arabian organizations. Among them, (15), depression (14 papers), HIV/ AIDS (10), diarrhea (10), epilepsy (10 papers), pneumonia (9), malaria (9), hepatitis (9 papers), etc. In terms of pharmacological activity, the largest research was focused on enzyme activity (with 125 papers), followed by anti-oxidant activity (87 papers), anti-neoplastic activity (70 papers), anti-inflammatory activity (54 papers), anti-microbial activity (40 papers), antibacterial activity (27 papers), anti-fungal activity (22 papers), analgesic activity (20 papers), anti-viral activity (17 papers), etc. The top 15 most productive Saudi Arabian organizations involved in pharmaceutical research together have published 1336 during 2001-10, accounting for 96.39% share in the cumulative publications output of Saudi Arabia, with an average of 89.6 papers per organizations. The average citation per paper and average h-index registered by the total papers of these 15 Saudi Arabian organizations were 3.41 (varying from 1 to 5.21) and 10.60 (varying from 4 to 27). The 15 most productive authors have together contributed a total of 419 papers (varying from 15 to 85), constituting 30.23% share of the total output of Saudi Arabia and registering an average productivity per author of 27.93. The average citation per paper and average h-index registered by the total papers of these 15 Saudi Arabian authors were 3.69 (varying from 1.83 to 7.47) and 9.06 (varying from 4 to 16). The top 15 journals where Saudi Arabian scientists have published together contributed 524 papers in pharmaceutical science, which accounted for 37.81% of the total output of Saudi Arabia during 2001-10, decreasing from 45.50% during 2001-05 to 32.48% during 2006-10. There are 19 Saudi Arabian papers, which have received 50 or more citations since their publication. These 19 high cited papers have received an average of 82.42 citations per paper and the citation range of these papers varies from 50 to 227. These 19 high cited papers involve 7 Saudi Arabian organizations and have appeared in 15 journals.
Conclusion
There is a need to improve the number of publications in order to measure Saudi Arabia's research in pharmaceutical sciences. As most of the universities and major organizations are speeding up in a setting research atmosphere all over country it is obvious, based on fact of Globalization of Research and education, Saudi Arabia will emerge as one of the productive countries in terms of pharmaceutical research. Rigorous efforts are still necessary with respect to research productivity, international collaborations, multi cultured research environ-ment, cutting edge drug discovery and quality research. It is now clear, that the number of research output in terms of publications has seen a tremendous growth in last 2-3 years. We foresee that Saudi Arabia will become the most productive country in the near future.
